Appili Therapeutics – Press Release Correction
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) has issued a correction to its October 10, 2024 press release regarding the proposed arrangement with Aditxt, Inc. The initial press release incorrectly stated the cash consideration for each Appili share as US$ 0.467. The correct cash amount is US$ 0.0467 per Appili Share.
Under the corrected terms of the arrangement, for each Class A common share of Appili, shareholders will receive:
- US$ 0.0467 in cash
- 0.0000686251 of a share of Aditxt common stock (valued at approximately US$0.00013 per Appili Share based on Aditxt's closing price on October 3, 2024)
This correction is significant as it substantially reduces the cash component of the consideration for Appili shareholders in the proposed arrangement with Aditxt, Inc.
Positive
- None.
Negative
- Cash consideration for Appili shareholders reduced from US$ 0.467 to US$ 0.0467 per share
- Total value of consideration per Appili share (cash + stock) decreased to approximately US$ 0.047 from US$ 0.467
Details
News Market Reaction – APLIF
The recorded move for APLIF in the trading session of this news was +19.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), announces correction to its press release entitled “Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders” issued on October 10, 2024 (the “Initial Press Release”).
The Initial Press Release, incorrectly stated that under the terms of the proposed arrangement with Aditxt, Inc. (the “Arrangement”), for each Class A common share of the Company (“Appili Shares”), shareholders will receive (i) US
This press release should be read in conjunction with the Initial Press Release and is subject to the forward looking statement disclaimer set out in the Initial Press Release. These corrections do not change any other information reported in the Initial Press Release.
Media Contact:
Jenna McNeil, Communications Manager
Appili Therapeutics
E: JMcNeil@AppiliTherapeutics.com
Investor Relations Contact:
Don Cilla, President and CEO
Appili Therapeutics
E: Info@AppiliTherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.